Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abbott LaboratoriesXSWX:ABT -5.81%70 EV-to-EBIT is 21.35 as of Jul. 16, 2026, which is 30% below its 10-year median of 30.33. GuruFocus rates XSWX:ABT with a GF Score™ of 70/100 and a GF Value™ of CHF106.67. The stock has 1 warning sign investors should review. Among 465 Medical Devices & Instruments companies, Abbott Laboratories ranks worse than 57.42% on this metric.
The historical rank and industry rank for Abbott Laboratories's EV-to-EBIT or its related term are showing as below:
XSWX:ABT'
s EV-to-EBIT Range Over the Past 10 Years
Min: 17.54 Med: 30.33 Max: 51.78
Current: 21.09
During the past 13 years, the highest EV-to-EBIT of Abbott Laboratories was 51.78. The lowest was 17.54. And the median was 30.33.
XSWX:ABT's EV-to-EBIT is ranked worse than 57.42% of 465
companies
in the Medical Devices & Instruments industry
Industry Median: 18.93
vs XSWX:ABT: 21.09
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Abbott Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was CHF165,265 Mil.
Abbott Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF6,931 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories EV-to-EBIT Related Terms
Abbott Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Abbott Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Abbott Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories's EV-to-EBIT falls into.
Abbott Laboratories's current Enterprise Value is CHF147,996 Mil.
Abbott Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF6,931 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (XSWX:ABT) has a EV-to-EBIT of 21.35 as of Jul. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Abbott Laboratories and its competitors. This is 30% below median its historical median of 30.33. Over the past decade, Abbott Laboratories' EV-to-EBIT has ranged from 17.54 to 51.78. According to the industry distribution chart, Abbott Laboratories ranks #267 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 57.4%.
Is Abbott Laboratories' EV-to-EBIT too high?
Abbott Laboratories' current EV-to-EBIT of 21.35 is 30% below median its 10-year median of 30.33. Over the past 10 years, this metric has ranged from a low of 17.54 to a high of 51.78. The Medical Devices & Instruments industry median EV-to-EBIT is 18.93. Abbott Laboratories' value of 21.35 is 12.8% above this industry median. Based on the distribution chart, Abbott Laboratories ranks #267 out of 465 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Abbott Laboratories has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' EV-to-EBIT compare to SYK and MDT?
According to the Medical Devices & Instruments industry distribution chart, Abbott Laboratories ranks #267 out of 465 companies for EV-to-EBIT. This places Abbott Laboratories in the lower half of its industry. The industry median EV-to-EBIT is 18.93. Abbott Laboratories' value of 21.35 is 12.8% above this benchmark. Historically, Abbott Laboratories' own EV-to-EBIT has ranged from 17.54 to 51.78 over the past decade. While the company's 10-year median is 30.33 vs. the industry median of 18.93, Abbott Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.93, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories's current EV-to-EBIT of 21.35 is 12.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Abbott Laboratories and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories's current EV-to-EBIT is 21.35, which is 30% below median its own 10-year median of 30.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Abbott Laboratories (XSWX:ABT) has a current EV-to-EBIT of 21.35. The stock's GF Value™ is CHF106.67, compared to a current price of CHF73.00 — trading 31.6% below its estimated fair value. The current EV-to-EBIT is 21.35, which is 30% below median its 10-year median of 30.33 and 12.8% above the Medical Devices & Instruments industry median of 18.93. Abbott Laboratories' overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Abbott Laboratories (XSWX:ABT), the current EV-to-EBIT is 21.35 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (XSWX:ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of CHF73.00 is trading 31.6% below its estimated GF Value™ of CHF106.67.
Key valuation signals for XSWX:ABT:
EV-to-EBIT: 21.35 (30% below median its 10-year median of 30.33)
GF Value™: CHF106.67 vs. price of CHF73.00 (31.6% below fair value)
Industry Position: 12.8% above the Medical Devices & Instruments median (#267 of 465)
No single metric tells the full story. See the XSWX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
70GF Score
Get the complete analysis for XSWX:ABT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ABT has been successfully added to your 
